Our aims and objectives

WDC aims to overcome barriers to research and innovation; to increase global investment in dementia; to improve treatment and care for people with dementia; and to meet the G8 Dementia Summit’s commitment to find a cure or disease-modifying medicine by 2025.

WDC's historic impact

  • WDC helped shape the UK-Government-led work to establish the Dementia Discovery Fund (DDF). The DDF is a ground-breaking venture capital fund set up to boost investment in dementia by bringing together investors from private, public and philanthropic sectors to identify, invest in and advance early stage (pre-clinical) drug development projects
  • Raj Long, working with the UK government, facilitated and chaired meetings with eleven international regulators from ten global jurisdictions, who agreed to work collaboratively to improve dementia drug development. They identified five key work streams and continue to make progress. The international regulators also continue to liaise and meet to discuss dementia. This is now facilitated by OECD, one of WDC’s associate members and partner organisations
  • WDC acted as a catalyst for the World Health Organization’s (WHO) prioritisation of dementia, through its participation in the first WHO ministerial conference on dementia in March 2015; and its support for a WHO resolution on dementia in May 2016; for the creation of a Global Dementia Observatory, to be launched in 2017; and for the WHO Global Action Plan on the Public Health Response to Dementia, which will be approved at the World Health Assembly in May 2017

WDC's future impact

If we project forward twelve months: 

  • The WDC global finance team will have acted to increase and diversify expenditure on dementia research
  • The WDC global care team will have published a statement on the importance of and principles for quality care and support for those affected by dementia; and developed and distributed recommendations on the care and support research needs that would potentially generate the most impact and benefit for people living with dementia and their caregivers
  • The WDC global risk reduction team will have raised awareness of dementia in low and middle income countries (LMICs), including by influencing global healthy ageing and brain health programmes; by facilitating a risk reduction pilot project in Indonesia; and by supporting research into dementia awareness in Pakistan  
  • The WDC global research team will have encouraged more countries to partner with the EU Joint Programme - Neurodegenerative Disease Research (JPND); encouraged industry partners to enable open science; and encouraged a more collaborative approach to data sharing, including by organising a two-day conference in Autumn 2017 
  • WDC will also have been a key partner in the roll-out of the WHO’s Global Action Plan on the Public Health Response to Dementia; the Global Dementia Observatory (GDO); and other initiatives
  • Achievements

    Since its formation in 2014, WDC has helped shape the UK-Government-led work to establish the Dementia Discovery Fund (DDF); facilitated and chaired meetings with international regulators from global jurisdictions for the first time, who continue to work collaboratively to improve dementia drug development; and acted as a catalyst for the World Health Organization’s (WHO) prioritisation of dementia, including through the creation of a Global Dementia Observatory and the Global Action Plan on the Public Health Response to Dementia.